Overview

Gender

male

For the past 20 years, Dr. January has been a leading international authority in the field of cardiac arrhythmias, including long QT syndrome.

Dr. January's work has had significant industry and regulatory impact, and he has consulted to multiple large and small pharmaceutical companies.

He was one of the first scientists to stably express hERG potassium channels in a human cell system (HEK293 cells), and these cells are now distributed world-wide for use in drug toxicity screening.

His work helped to identify drugs that caused high-affinity hERG potassium channel block, and his studies helped lead to the withdrawal of several QT interval prolonging drugs from the marketplace.

Screening of new drugs and lead compounds for this hERG liability is now a broadly established technology required by regulatory agencies worldwide.

Dr. January's technology is the basis for CDI's hERG screening program.

Dr. January holds an MD and PhD in Physiology and Biophysics from the University of Iowa.

He is a practicing cardiologist and is a Professor in the Department of Medicine in the Division of Cardiovascular Medicine at the University of Wisconsin-Madison, School of Medicine and Public Health.